HERANTIS PHARMA

Company presentation

Herantis Pharma is an innovative biotech company developing disease modifying therapies for Parkinson's disease

www.herantis.com

Forward-looking statement

This company presentation includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis' future financial position and results of operations, the company's strategy, objectives, future developments in the markets in which the company participates or is seeking to participate or anticipated regulatory changes in the markets in which the company operates or intends to operate. In some cases, forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "guidance," "intend," "may," "plan," "potential," "predict," "projected," "should" or "will" or the negative of such terms or other comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future.

Forward-looking statements are not guarantees of future performance and are based on numerous assumptions. The company's actual results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, may differ materially from (and be more negative than) those made in, or suggested by, the forward-looking statements contained in this company release. Factors, including risks and uncertainties that could cause these differences include, but are not limited to risks associated with implementation of Herantis' strategy, risks and uncertainties associated with the development and/or approval of Herantis' drug candidates, ongoing and future clinical trials and expected trial results, the ability to commercialize drug candidates, technology changes and new products in Herantis' potential market and industry, Herantis' freedom to operate in respect of the products it develops (which freedom may be limited, e.g., by competitors' patents), the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. In addition, even if Herantis' historical results of operations, including the company's financial condition and liquidity and the development of the industry in which the company operates, are consistent with the forward-looking statements contained in this company release, those results or developments may not be indicative of results or developments in subsequent periods.

Herantis – at a glance

Developing a **disease-modifying therapy** to address the unmet clinical need in Parkinson's disease and other neurodegenerative diseases



Lead asset **HER-096** is a small engineered peptide molecule **with a unique mechanism of action and an easy route of administration**

Safety and blood-brain barrier (BBB) penetration data in humans expected in 2H 2023

Founded in Helsinki, Finland in 2008; Listed at Nasdaq First North Helsinki

Experienced board and management team; 10 employees including 5 PhD's.

Scientific advisory board with **globally leading experts in Parkinson's disease** from industry and academia

HERANTIS PHARMA

Herantis investment proposition

Lead asset	• **HER-096 has the potential to become a therapy for Parkinson's disease with a unique, disease modifying Mechanism of Action**
Market	• **Over 8 million patients globally** (source: www.epda.eu.com) • **Unmet need: no disease modifying therapies for Parkinson's disease today**
Evidence	• **HER-096 rescues dopaminergic neurons and passes the BBB in animals** • **CDNF preclinical and clinical data de-risk the development**
Strategy	• **Partnering Opportunity after the planned HER-096 Phase 1 clinical study: Blood Brain Barrier penetration and safety in humans**

HERANTIS PHARMA

HER-096: Disese-modifying therapy for Parkinson's disease

PARKINSON'S DISEASE (PD)

- Degeneration of dopaminergic nerve cells in mid brain cause severe motor and non-motor symptoms
- At the time of diagnosis, approximately half of the dopaminergic activity is lost

CURRENT TREATMENTS CANNOT STOP THE PROGRESSION OF PD

- For 50 years, the mainstay of Parkinson's treatment has been levodopa, which helps to restore dopamine levels in the brain

OVER $10B MARKET

- Currently 8-10 million patients globally; increasing rapidly
- Current market $5B, estimated to grow to $11B by 2029 driven by disease-modifying drugs (source: GlobalData)

UNMET NEED: DISEASE-MODIFYING TREATMENTS

BLOOD-BRAIN BARRIER (BBB) PROTECTS THE BRAIN – DIFFICULT TO DELIVER DRUGS TO THE TARGET TISSUE

- 95% of pharmaceuticals cannot pass the BBB
- Many promising therapeutic candidates cannot be administered to patients so that they would reach the targets in the brain



HERANTIS' HER-096

- Disease-modifying therapy for PD
- Unique mechanism of action
- Promising preclinical efficacy data
- Subcutaneous administration: Efficient BBB penetration (preclinical data)

HERANTIS PHARMA

HER-096 is a perfect drug candidate for Parkinson's disease (PD)

HER-096

- Designed based on the active site of the protein CDNF, a known ER protein and unfolded protein response (UPR) modulator
- Neuroprotection, restores proteostasis and reduces neuroinflammation
- Synthetic peptidomimetic molecule, straightforward CMC

Strong preclinical evidence

- Effectively passes through the blood-brain barrier *in vivo* with extended CSF to plasma half-life (s.c. administration)
- *In vivo* evidence of target modulation and effect on motor functions in an α-synuclein disease model

Moving to clinical studies

- Preclinical toxicology studies (GLP) completed (rats, dogs) – no signs of systemic toxicity
- Phase 1a planned to start in 1H 2023



HERANTIS PHARMA

HER-096 has a unique multimodal disease modifying mechanism of action





HERANTIS PHARMA

HER-096 improves motor function in mouse PD model (α-synuclein fibril model)

Mouse bar test to observe motor coordination

- Mouse walks from right to left
- Longer walking time corresponds to compromised motor coordination
- Video still image shows where the mice are at certain point of time
- **Mouse 1**: normal aged mouse ➔ no challenges in crossing the bar
- **Mouse 2**: aged mouse in which pathology induced 6 weeks prior to the video shoot ➔ compromized function
- **Mouse 3**: aged mouse in which pathology induced 6 weeks prior to video shoot and treated 5 weeks with subcutaneous HER-096 ➔ quicker than the control!
- The original video is available by using the link https://youtu.be/L3WmkhP2Opw



Disease modification & improved motor function ➔ potential to become first-in-class treament of Parkinson's disease

HERANTIS PHARMA

HER-096 animal data confirm its unique MoA and brain penetration

HER-096's unique MoA confirmed in mouse PD model

HER-096 **improves** dopamine neuronal survival



HER-096 **decreases** the amount of α-synuclein aggregates



HER-096 **reduces** neuroinflammation



HER-096 penetrates the brain in small and large animals following a single subcutaneous injection

- ✓ **Efficient brain penetration** confirmed in mice, rats, and dogs
- ✓ Pharmacologically active concentration is easily achieved in the brain / cerebrospinal fluid

DUAL (BRAIN AND PLASMA) MICRODIALYSIS STUDY IN RATS



HER-096 has extended half-life in brain compared to plasma

Plasma $T_{1/2}$ = 0.5 h

Brain ISF $T_{1/2}$ = 1.3 h

HERANTIS PHARMA

Herantis strategy and achivements during 2022

Strategy

- **Create value in preclinical & early clinical development**
- **Pursue partnering opportunities for HER-096**

2022

- **Encouraging preclinical efficacy and blood-brain barrier penetration**
- **Submission of clinical trial application (CTA)**
- **Selected for European Innovation Council (EIC) grant of €2.5 million through their prestigious EIC Accelerator, with the option to receive additional funding through equity investments.**

HERANTIS PHARMA

2023 development milestones for HER-096

Milestone	Expected timing
• Phase 1a clinical trial application (CTA) regulatory approval • First HER-096 human dose in Phase 1a study • First HER-096 preclinical publication	**1H 2023**
• Phase 1a read-out: Evidence of HER-096 safety and blood-brain barrier penetration in humans	**2H 2023**

Herantis is fully funded through these milestones

HERANTIS PHARMA

Contact details

CEO Antti Vuolanto, antti.vuolanto@herantis.com
CFO Tone Kvåle, tone.kvale@herantis.com

HERANTIS PHARMA